Physicians' Academy for Cardiovascular Education

Pooled analysis of three trials with PCSK9 siRNA in patients with HeFH or ASCVD

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

Literature - Wright RS, Ray KK, Raal FJ et al. - J Am Coll Cardiol. 2021 Mar 9;77(9):1182-1193. doi: 10.1016/j.jacc.2020.12.058.

Introduction and methods

Reasons for failure to achieve LDL-c target levels include poor adherence and suboptimal use of efficacious lipid-lowering regimens [1]. Effective LDL-c lowering therapies in addition to statins that facilitate adherence are of interest as 80% of patients on statins with established ASCVD do not reach guideline recommended LDL-c goals [2-5].

Inclisiran is a siRNA that suppresses PCSK9 translation in the liver and lowers circulating concentrations of PCSK9 and LDL-c with twice-yearly dosing [6]. Three phase 3, placebo-controlled, double-blind, randomized trials investigated the efficacy and safety of inclisiran in patients with heterozygous familial hypercholesterolemia (HeFH) (ORION-9, n=482), ASCVD (ORION-10, n=1561), or ASCVD and ASCVD risk equivalents (ORION-11, n=1617) [7,8]. The current analysis provided patients-level pooled efficacy and safety data from the three trials of inclisiran versus placebo (n=3660). Participants were aged ≥18 years and had elevated LDL-c levels despite receiving maximally tolerated statins with or without other LDL-c-lowering therapies, such as ezetimibe. Participants were randomized 1:1 to receive either inclisiran sodium 300 mg or placebo administered as a subcutaneous injection on days 1 and 90, followed by doses at 6-month intervals, on days 270 and 450. The pre-specified coprimary endpoints included placebo-corrected percentage change in LDL-c from baseline to day 510 and the time-adjusted placebo-controlled percentage change in LDL-c after day 90 up to day 540 (average of all measurements over this time period).

Main results


This pooled analysis of ORION-9, ORION-10 and ORION-11 showed that inclisiran administered subcutaneously twice-yearly reduced LDL-c on average by 50.7% compared to placebo in patients with ASCVD, ASCVD risk equivalence, or HeHF on maximally tolerated statins. Injection site reactions and bronchitis occurred more often in the inclisiran group compared to the placebo group. Other safety outcomes were similar between groups.


Show references

Find this article online at J Am Coll Cardiol.

Share this page with your colleagues and friends: